FeesSafety
Pluang+

Lexeo reports strong interim Phase I/II results for LX2020 in heart disease, plans pivotal study with FDA support

Company Fundamentals
16 Nov 2026, 14:00 WIB
GlobeNewsWire
View Source
Bullish
Lexeo reports strong interim Phase I/II results for LX2020 in heart disease, plans pivotal study with FDA support

Lexeo Therapeutics announced positive interim data from its Phase I/II trial of LX2020 for PKP2 arrhythmogenic cardiomyopathy, showing an 80% reduction in non-sustained ventricular tachycardia and 44% reduction in premature ventricular contractions in high-dose patients. The treatment was well tolerated with no significant safety issues. The FDA is open to using non-sustained ventricular tachycardia as a primary endpoint for accelerated approval. Lexeo plans to finalize pivotal study design and expects to start this study in the second half of 2027, supported by $219 million in cash to fund operations into 2028.

Lexeo Therapeutics' recent financial update and trial progress come as 66 of 150 priced Health-sector US stocks on Pluang rose while 50 fell, showing a mixed market on November 16, 2026, at 18:12 WIB. Notable price changes include Dyne Therapeutics Inc. (DYN) up 1.98% to USD 17.50 and Amneal Pharmaceuticals Inc. Class A (AMRX) down 2.06% to USD 20.94. For readers following Health-sector stocks, here is Pluang's market snapshot as of that time.

More News

GitGuardian expands program to alert companies of leaked credentials, boosting enterprise cybersecurity worldwide.

GitGuardian expands program to alert companies of leaked credentials, boosting enterprise cybersecurity worldwide.

GitGuardian has launched the Enterprise Good Samaritan Program to identify and notify companies about high-impact leaked credentials that could expose their systems to attackers. Using AI and expert analysis, the program traces leaks to affected orga...

Market News
Neutral
22 minutes ago
Saputo renews share buyback plan to repurchase up to 10% of public shares by Nov 2027

Saputo renews share buyback plan to repurchase up to 10% of public shares by Nov 2027

Saputo Inc. has renewed its Normal Course Issuer Bid (NCIB), allowing it to repurchase up to 22.5 million common shares, representing 10% of its public float, from November 19, 2026, to November 18, 2027. This move reflects Saputo's strategy to retur...

Company Fundamentals
Bullish
22 minutes ago
Saputo renews share buyback program to repurchase up to 10% of public shares through Nov 2027.

Saputo renews share buyback program to repurchase up to 10% of public shares through Nov 2027.

Saputo Inc. announced the renewal of its normal course issuer bid, allowing it to repurchase up to 22.5 million ordinary shares, representing 10% of its public float, from November 19, 2026, to November 18, 2027. This move reflects Saputo's ongoing c...

Company Fundamentals
Bullish
22 minutes ago
Newcleo and Curio partner to supply recycled nuclear materials for advanced MOX fuel in US reactors

Newcleo and Curio partner to supply recycled nuclear materials for advanced MOX fuel in US reactors

Newcleo plc and Curio Legacy Ventures announced a collaboration to supply recycled nuclear materials for mixed-oxide (MOX) fuel production at Newcleo's planned US fuel manufacturing facility. This partnership combines Curio's NuCycle recycling techno...

Market News
Bullish
1 hour ago
Duke Robotics reports 38% revenue growth in Q3 2026 and expands IC Drone platform to Greece.

Duke Robotics reports 38% revenue growth in Q3 2026 and expands IC Drone platform to Greece.

Duke Robotics announced a 38% year-over-year revenue increase for Q3 2026, driven by its IC Drone insulator-cleaning activities. The company expanded its IC Drone platform into Greece through a strategic collaboration with CRONOS, identifying potenti...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App